T细胞受体库使用与HER2阳性乳腺癌双重靶向治疗反应的相关性
该研究基于NeoALTTO随机临床试验的245例HER2阳性乳腺癌患者基线肿瘤RNA测序数据,分析T细胞受体β链可变基因(TRBV)使用与病理完全缓解(pCR)的关系。结果显示,TRBV11-3高使用及TMG2(TRBV4.3、TRBV6.3、TRBV7.2高使用)与双HER2阻断治疗的更高pCR率相关,且在免疫富集和免疫贫乏肿瘤中均可见获益。
核心结论
- TRBV基因使用模式可能提供超越免疫基因特征的雙HER2阻断治疗反应信息。
- TRBV11-3或TRBV4.3、TRBV6.3、TRBV7.2高使用识别对双HER2靶向治疗反应更好的患者。
研究设计与样本
- NeoALTTO随机临床试验的二次分析,纳入245例HER2阳性乳腺癌患者基线肿瘤RNA测序数据。
- 患者接受紫杉醇联合拉帕替尼或曲妥珠单抗或两者双靶向新辅助治疗。
临床怎么用
- TRBV11-3或TMG2高使用可能辅助识别从双HER2靶向治疗中获益更多的HER2阳性乳腺癌患者。
- 免疫贫乏肿瘤中TMG2高表达者仍可能从双靶向治疗中获益,提示TRBV标志物可补充免疫基因特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified that is specifically associated with the benefit from dual HER2 blockade. OBJECTIVE: To examine if use of the T-cell β chain variable genes adds to the potential association of immune gene signatures with response to dual HER2 blockade. DESIGN, SETTING, AND PARTICIPANTS: In the NeoALTTO trial, HER2-positive patients recruited between January 5, 2008, and May 27, 2010, were treated with paclitaxel plus either lapatinib or trastuzumab or both as neoadjuvant therapy. In this study, RNA sequencing data from baseline tumor specimens of 245 patients in the NeoALTTO trial were analyzed and reads were aligned to TRBV gene reference sequences using a previously published Basic Local Alignment Search Tool T-cell receptor mapping pipeline. Total TRBV gene use, Shannon entropy, and gene richness were calculated for each tumor, and nonnegative matrix factorization was used to define TRBV co-use metagenes (TMGs). The association between TRBV metrics, tumor genomic metrics, and response was assessed with multivariable logistic regression. Statistical analysis was performed from January 23 to December 2, 2017. MAIN OUTCOMES AND MEASURES: The association between TRBV use metrics and pCR. RESULTS: Among the 245 women with available data (mean [SD] age, 49 [11] years), total TRBV use correlated positively with a gene expression signature for immune activity (Spearman ρ = 0.93; P < .001). High use of TRBV11-3 and TMG2, characterized by high use of TRBV4.3, TRBV6.3, and TRBV7.2, was associated with a higher rate of pCR to dual HER2-targeted therapy (TRBV11-3 interaction: odds ratio, 2.63 [95% CI, 1.22-6.47]; P = .02; TMG2 interaction: odds ratio, 3.39 [95% CI, 1.57-8.27]; P = .004). Immune-rich cancers with high TMG2 levels (n = 92) had significantly better response to dual HER2-targeted treatment compared with the single therapy arms (rate of pCR, 68% [95% CI, 52%-83%] vs 21% [95% CI, 10%-31%]; P < .001), whereas those with low TMG2 levels did not benefit from dual therapy. High TMG2 levels were also associated with a higher rate of pCR to the combined therapy in immune-poor tumors (n = 30; pCR, 50% [95% CI, 22%-78%] vs 6% [95% CI, 0%-16%]; P = .009). CONCLUSIONS AND RELEVANCE: Use patterns of TRBV genes potentially provide information about the association with response to dual HER2 blockade beyond immune gene signatures. High use of TRBV11.3 or TRBV4.3, TRBV6.3, and TRBV7.2 identifies patients who have a better response to dual HER2 targeted therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00553358.
引用
- Powles RL, Redmond D, Sotiriou C, et al. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29902299. doi:10.1001/jamaoncol.2018.1564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。